




The relative strengths and weaknesses of Bridgebio Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bridgebio Pharma Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 10% points. The greatest weakness of Bridgebio Pharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 143% points.

The company's Economic Capital Ratio, given in the ranking table, is 80%, being 149% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	797,749
Cost of Goods Sold	20,962
Intangible Assets	28,077
Liabilities, Current	287,971
Liabilities, Non-Current	17,135
Other Assets	104,833
Other Compr. Net Income	8,011
Other Expenses	21,782
Other Liabilities	2,707,500
Other Net Income	-209,092
Other Revenues	502,076
Property and Equipment	5,366
Research and Development	451,953
Selling, General and Administrative Expense	531,225

Output Variable	Value in 1000 USD
Assets	936,025
Liabilities	3,012,606
Expenses	1,025,922
Revenues	502,076
Stockholders Equity	-2,076,581
Net Income	-732,938
Comprehensive Net Income	-728,932
BaseVar	2,846,866
ECR before Limited Liability	-266%
Economic Capital Ratio	80%